Zoetis Inc. (NYSE:ZTS) reached a new 52-week high during trading on Monday . The stock traded as high as $52.43 and last traded at $52.38, with a volume of 901,903 shares changing hands. The stock had previously closed at $51.98.

Several equities research analysts recently commented on ZTS shares. Zacks Investment Research cut Zoetis from a “buy” rating to a “hold” rating in a report on Wednesday, May 11th. Guggenheim reaffirmed a “buy” rating and issued a $60.00 price target on shares of Zoetis in a report on Monday, July 18th. Jefferies Group increased their price target on Zoetis from $58.00 to $60.00 and gave the company a “buy” rating in a report on Thursday, August 4th. Citigroup Inc. cut Zoetis from a “buy” rating to a “neutral” rating and increased their price target for the company from $46.00 to $50.00 in a report on Friday, June 10th. They noted that the move was a valuation call. Finally, Goldman Sachs Group Inc. cut Zoetis from a “neutral” rating to a “sell” rating and increased their price target for the company from $46.00 to $48.00 in a report on Friday, May 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Zoetis currently has a consensus rating of “Buy” and an average price target of $54.63.

The stock’s 50-day moving average price is $49.42 and its 200-day moving average price is $45.97. The company has a market capitalization of $25.96 billion and a PE ratio of 40.83.

Zoetis (NYSE:ZTS) last posted its earnings results on Wednesday, August 3rd. The company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. During the same period in the previous year, the company posted $0.43 EPS. The company earned $1.20 billion during the quarter, compared to analysts’ expectations of $1.17 billion. Zoetis’s quarterly revenue was up 2.8% compared to the same quarter last year. Equities research analysts anticipate that Zoetis Inc. will post $1.90 EPS for the current year.

Other large investors recently bought and sold shares of the company. Calvert Investment Management Inc. raised its stake in Zoetis by 24.8% in the fourth quarter. Calvert Investment Management Inc. now owns 28,411 shares of the company’s stock worth $1,361,000 after buying an additional 5,639 shares during the last quarter. Greenwood Capital Associates LLC bought a new stake in Zoetis during the fourth quarter worth about $1,532,000. KBC Group NV raised its stake in Zoetis by 19.5% in the fourth quarter. KBC Group NV now owns 226,507 shares of the company’s stock worth $10,854,000 after buying an additional 37,018 shares during the last quarter. King Luther Capital Management Corp bought a new stake in Zoetis during the fourth quarter worth about $6,256,000. Finally, BlackRock Advisors LLC raised its stake in Zoetis by 8.7% in the fourth quarter. BlackRock Advisors LLC now owns 2,523,641 shares of the company’s stock worth $120,932,000 after buying an additional 202,029 shares during the last quarter.

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.